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To identify and quantify associations between baseline characteristics on hospital admis-
sion and mortality in patients with COVID-19 at a tertiary hospital in Spain.
Methods and findings
This retrospective case series included 238 patients hospitalized for COVID-19 at Hospital
Universitario Clı́nico San Cecilio (Granada, Spain) who were discharged or who died. Elec-
tronic medical records were reviewed to obtain information on sex, age, personal anteced-
ents, clinical features, findings on physical examination, and laboratory results for each
patient. Associations between mortality and baseline characteristics were estimated as haz-
ard ratios (HR) calculated with Cox regression models.
Series mortality was 25.6%. Among patients with dependence for basic activities of daily
living, 78.7% died, and among patients residing in retirement homes, 80.8% died. The vari-
ables most clearly associated with a greater hazard of death were age (3% HR increase per
1-year increase in age; 95%CI 1–6), diabetes mellitus (HR 2.42, 95%CI 1.43–4.09), SatO2/
FiO2 ratio (43% HR reduction per 1-point increase; 95%CI 23–57), SOFA score (19% HR
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increase per 1-point increase, 95%CI 5–34) and CURB-65 score (76% HR increase per 1-
point increase, 95%CI 23–143).
Conclusions
The patients residing in retirement homes showed great vulnerability. The main baseline
factors that were independently associated with mortality in patients hospitalized for
COVID-19 were older age, diabetes mellitus, low SatO2/FiO2 ratio, and high SOFA and
CURB-65 scores.
Introduction
Since 11 March 2020, when the World Health Organization (WHO) declared a worldwide
SARS-CoV-2 pandemic, there have been more than 213,000 confirmed cases in Spain (as of 25
April 2020) and 22,157 deaths, representing a mortality rate of 47 per 100,000 inhabitants [1].
Different reports on the status of the COVID-19 epidemic published in Spain by the Ministry
of Health indicate that this disease is slightly more prevalent in women, in people older than
50 years, and in people with two or more previous illnesses, particularly hypertension (HT)
(47.4%), cardiovascular disease (CVD) (32.3%), and diabetes mellitus (DM) (16.1%) [2,3].
Among confirmed cases of infection, 48.7% patients have required hospitalization mainly
for pneumonia and adult respiratory distress syndrome (ARDS). Among patients with pneu-
monia, men, people older than 60 years, and people with CVD and/or DM are overrepresented
[4,5]. Among Spanish patients the most frequent symptoms have been fever (75.7%), cough
(75.5%) and dyspnoea (48.3%) [6]. In 5% of hospitalized patients, the clinical course pro-
gressed to critical status requiring admission to the intensive care unit, and 2.3% have died
[7,8].
Radiographic findings in patients with pneumonia are highly variable depending on–
among other factors–the time elapsed since symptom onset [9,10]. However, the most frequent
findings are bilateral infiltrates with an interstitial or ground glass pattern, or bilateral alveolar
opacities [11,12]. Alterations in laboratory values are also frequent and varied, depending on
disease severity, e.g. anaemia, leucocytosis, neutrophilia, lymphopenia, and elevated creatinine,
erythrocyte sedimentation velocity (ESV), C-reactive protein (CRP), procalcitonin, lactate
dehydrogenase (LDH), serum ferritin, troponins, and cytokines (among other markers)
[12,13]. The most frequent laboratory findings in seriously ill patients are lymphopenia,
hypoalbuminemia, and increased ferritin and D-dimer; most of these alterations probably
reflect increases in cytokines levels or the “cytokine storm” phenomenon (IL-2R, IL-6, IL-10
and TNFα) [14,15].
Few studies to date have shed light on the main factors associated with fatality rates in hos-
pitalized patients. Most notably, a retrospective cohort study of 191 patients at two hospitals in
China reported 41 deaths, and analysed the association of sex, age, chronic obstructive lung
disease, coronary disease, diabetes, hypertension, chronic kidney disease, and other comorbid-
ities on the risk of death due to COVID-19. According to the multivariate models in this
study, associations were detected only for patient age and two parameters measured on admis-
sion: Sequential Organ Failure Assessment (SOFA) score and D-dimer concentration greater
than 1 μg/ml [16]. Other studies in similar conditions were made for Middle East respiratory
syndrome (MERS) [17] and severe acute respiratory syndrome (SARS) [18] but the number of
studies analysing prognosis factors on COVID-19 remain insufficient to date.
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The aim of this study was to identify and quantify the associations between baseline charac-
teristics on hospital admission in patients with COVID-19 infection (e.g. personal antecedents,
physical examination and clinical findings, and laboratory results) and mortality at a tertiary
hospital in Spain.
Materials and methods
This retrospective case series comprised 238 patients admitted for COVID-19 to Hospital Uni-
versitario Clı́nico San Cecilio, and who died or were discharged, between 16 March and 10
April 2020. This 480-bed tertiary hospital is located in the city of Granada (southern Spain),
and provides specialized health care services to a total population of 291,797 inhabitants. Only
positive PCR test was considered as diagnosis criteria for the patients included in our series.
Therefore, patients presenting compatible symptoms and negative test were not included in
the present study. The information detailed below was collected from electronic medical rec-
ords for each patient.
General information on admission and recorded in the emergency service
report
Sex, age (analysed as a continuous variable and also stratified into groups of 30–39, 40–49, 50–
59, 60–69, 70–79, and 80 years or older), presence of comorbidities (HT; DM; previous lung
disease; chronic kidney failure; CVD, or active neoplasia), dependence for basic activities of
daily living (BADL) (yes or no), clinical findings on admission (low-grade or higher fever, dry
cough, productive cough, haemoptysis, dyspnoea, anosmia, ageusia, headache, nausea, diar-
rhoea, other gastrointestinal symptoms, myalgia, fatigue, tiredness, general malaise, exan-
thema, odynophagia), smoking status (never smoker, current smoker, or ex-smoker) and place
of residence (own home or retirement facility).
Variables recorded from physical examination and laboratory tests on
admission
Systolic and diastolic blood pressure, heart rate, temperature, basal oxygen saturation (SatO2),
externally supplied oxygen (litres), fraction of inspired oxygen (FiO2), SatO2/FiO2 ratio, hae-
moglobin, lymphocyte count, neutrophil count, platelet count, D-dimer level, glycaemia, total
bilirubin, LDH, ferritin, CRP, procalcitonin, troponins, creatinine, kidney function (elevated
urea and creatinine), partial O2 and CO2 pressure in arterial blood (PO2 and PCO2), CO2, arte-
rial blood pH, SOFA score, CURB-65 score, and X-ray findings on admission (categorized as
dichotomous variables), e.g. diffuse opacities, interstitial opacities, hilar congestion or pleural
effusion.
Analysis of outcome variables: Death and days of hospital stay
Central tendency and dispersion were estimated for quantitative variables, and frequency dis-
tribution was determined for categorical variables. For each category in the latter, we estimated
the distribution of discharges and deaths. Because our case series was defined on the basis of
outcomes (discharge or death), it cannot be considered a true cohort of admitted patients,
given that by definition we excluded patients who, at the end of the recruitment period (10
April 2020), remained hospitalized (censured data). For these patients the mean duration of
hospital stay can be assumed to be longer than for patients included in the present case series.
Because the length of hospital stay tends to be inversely associated with mortality, this associa-
tion would lead to selection bias, which in turn would result in overestimating the proportion
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of deaths in our sample. In addition, it could potentially skew (in either direction) the magni-
tude of the associations between patient characteristics on admission and death. To compen-
sate for this source of bias we opted to use time to death as a dependent variable and used Cox
proportional hazards regression models to calculate hazard ratios (HR) in order to quantify
the magnitude of associations between hazard or instantaneous death rate and patients’ base-
line characteristics.
Because of the low number of patients compared to the number of independent variables
considered in this analysis, we used a three-step modelling process. First, we developed sepa-
rate models for each baseline variable and for age. Next we defined subgroups of baseline vari-
ables (sociodemographic, symptoms, comorbidities, physical examination on admission,
laboratory values, and X-ray findings), and used a stepwise process to build multivariate mod-
els for each variable (including age in all models). The variables selected in each model where
then used in a stepwise procedure to build a final model that included baseline variables that
were retained. In all cases the P value for inclusion in the model was set at 0.05, and the P value
for exclusion was set at 0.10. The 95%CI was calculated for each HR. All data were analysed
with STATA software (version 15.0) [19].
Ethics
This study met the requirements for appropriateness to achieve the intended aims and com-
plied with all ethical principles pertinent to this type of study design. All data were fully anon-
ymized before the analyses. No informed consent was required due to the characteristics of the
design. The study was approved by the Research Ethics Committee of Granada province (CEI)
on 13 April 2020.
Results
Slightly more than half of our patients were males (55.0%, n = 131). The age range was 24 to 97
years with a mean of 64.7, standard deviation 15.4, and median 67 years. Most patients
(60.5%) were 60 years old or more, and the largest age stratum was 70 to 79 years. At least one
comorbidity was present on admission in 56.7% of the sample. Among the most prevalent dis-
eases were HT (48.7%), DM (21.9%), and CVD (22.7%). About one fifth of the patients
(19.8%) had dependence for BADL, and 10.9% lived in retirement homes (Table 1). On admis-
sion, the most frequent clinical profile was characterized by low-grade fever (89.5%), dry
cough (80.7%), general malaise (63.5%), dyspnoea (61.3%) and tiredness (59.2%) (Table 1).
Also shown in Table 1 are the proportions of deaths in the entire sample and for each cate-
gory of baseline variables. About one fourth of the patients in the present series died (25.6%).
No patients younger than 50 years died; as age increased, the proportion of deaths increased in
an approximately exponential manner, e.g. 5.8% in patients aged 50 to 59 years (95%CI 1.2–
15.9), 12.8% in those aged 60 to 69 (95%CI 4.8–25.7), 28.6% in those aged 70 to 79 (95%CI
16.6–43.3), and 79.2% in those 80 years old or more (95%CI 65.0–89.5). In our series only
5.8% (6 out of 103) of the patients with no prior comorbidities died. In contrast, 78.7% of our
patients with dependence for BADL and 80.8% of those who resided in retirement homes
died.
Tables 2 and 3 show the HR estimated with Cox stepwise regression models to quantify the
association between hazard of death and variables recorded on admission (see Methods).
Table 2 show the baseline variables regarding demographic data, comorbidities and medi-
cations, symptoms, physical exam and X-Ray findings on admission. The variables included in
the final model as associated with higher mortality were age (3% increase in HR per 1-year
increase in age; 95%CI 1–6), DM (HR 2.42; 95%CI 1.43–4.09. Elevated SatO2/FiO2 ratio was
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inversely related with mortality (43% decrease per 1-point increase, 95%CI 23–57). None of
the other baseline variables were independently associated with mortality.
Table 3. show the laboratory parameters and prognostic scales on admission. The variables
included in the final model as associated with higher mortality were SOFA score (19% increase
per 1-point increase, 95%CI 5–34) and CURB-65 score (73% increase per 1-point increase, 95%
CI 23–143). None of the other baseline variables were independently associated with mortality.
Table 1. Sociodemographic and clinical characteristics, and distribution of deaths in each category.
Groups Category N % Deaths
N %1
Sociodemographic variables Men 131 55.0 38 29.0
Women 107 45.0 23 21.5
Age groups: 30–39 years 13 5.5 0 0
40–49 years 29 12.2 0 0
50–59 years 52 21.9 3 5.8
60–69 years 47 19.8 6 12.8
70–79 years 49 20.6 14 28.6
�80 years 48 20.2 38 79.2
Retirement home residence 26 10.9 21 80.8
Smoking Non-smoker 134 56.3 29 21.6
Current smoker 22 9.2 3 13.6
Ex-smoker 40 16.8 13 32.5
Comorbidities Any comorbidity 135 56.7 55 40.7
Hypertension 116 48.7 47 40.5
Diabetes mellitus 52 21.9 27 51.2
Cardiovascular disease 54 22.7 36 66.7
Prior lung disease 50 21.0 22 44.0
Chronic kidney failure 23 9.7 15 65.2
Active neoplasia 8 3.4 3 37.5
Multiple medications 77 32.4 39 50.7
Dependence for basic activities of daily living 47 19.8 37 78.7
Clinical findings Low-grade or higher fever 213 89.5 49 23.0
Dry cough 192 80.7 52 27.1
General malaise 151 63.5 42 27.8
Fatigue 141 59.2 32 22.7
Dyspnoea 146 61.3 43 29.5
Myalgia 105 44.1 15 14.3
Ageusia 55 23.1 1 1.8
Anosmia 48 20.2 2 4.2
Diarrhoea 70 29.4 8 11.4
Productive cough 62 26.1 16 25.8
Nausea 55 23.1 7 12.7
Headache 48 20.2 4 8.3
Odynophagia 23 9.7 6 26.1
Haemoptysis 8 3.4 1 12.5
Exanthema 3 1.3 0 0
Total 238 100 61 25.6
1 Percentage of deaths in each category of baseline variables.
https://doi.org/10.1371/journal.pone.0235107.t001
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Discussion
The sex and age distribution in our series of patients differs from that reported by the WHO
mission in China and from data published by the Spanish National Epidemiology Centre, both
Table 2. Hazard ratios for the association of baseline variables with hazard of death.
Group Variable1 HR2 95%CI HR3 95%CI HR4 95%CI
Demographic variables Male 1.34 0.80–2.27
Age1 1.09 1.07–1.12 1.09 1.07–1.11 1.03 1.01–1.06
Retirement home 1.19 0.64–2.22
Comorbidities and medications on admission BADL dependence 2.98 1.57–5.64 2.51 1.38–3.94
Hypertension 1.48 0.80–2.71
Diabetes mellitus 2.55 1.53–4.26 2.33 1.38–3.94 2.42 1.43–4.09
Prior lung disease 0.93 0.52–1.64
Chronic kidney failure 0.97 0.51–1.83
Cardiovascular disease 1.93 1.08–3.46
Multiple medications 1.57 0.90–2.74
Symptoms on admission Low-grade fever 0.61 0.32–1.16
Cough 1.40 0.69–2.84




Ageusia 0.11 0.02–0.83 0.11 0.02–0.83
Headache 1.25 0.40–3.88
Nausea 0.64 0.28–1.44




General malaise 1.28 0.74–2.21
Gastrointestinal symptoms 0.58 0.29–1.16
Fatigue 0.76 0.46–1.26
Duration of symptoms (days)1 0.98 0.91–1.05
Physical exam on admission Fever 2.00 1.11–3.60
Baseline SatO2
1 0.93 0.91–0.95




1 0.43 0.33–0.56 0.44 0.34–0.58 0.57 0.43–0.77
X-Ray findings on admission Opacities 2.93 1.24–6.92
Interstitial opacities 2.37 1.28–4.40 2.36 1.24–4.49
Hilar congestion 1.28 0.71–2.32
Pleural effusion 1.21 0.60–2.43
1 Quantitative variables. Hazard ratios are expressed as increments in the hazard of death per unit increase in the variable. For dichotomous variables, the reference
category was No or Absent.
2 Hazard ratios adjusted by age.
3 Hazard ratios obtained with stepwise regression models including age and the remaining variables in each group.
4 Hazard ratios obtained with a stepwise regression model including all variables retained in the models fitted for each group of variables.
BADL, Basic activities of daily living.
https://doi.org/10.1371/journal.pone.0235107.t002
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of which found very similar figures [7,20]. In the present series the proportion of men was
larger (55% vs. 51% in China) and median age was greater (67 years vs. 51 years in China).
Our figures can be attributed in part to the greater population aging in Spain, where people
aged 65 years or more account for nearly 50% of the population vs. 12% in China [21]. In addi-
tion, evolution of the pandemic in Spain has lagged behind China, and this may mean that
because the patients in our series are among the first in Spain for whom these early outcomes
(discharge or death) are reported, our sample comprises a high proportion of patients with fac-
tors potentially associated with more severe illness: male sex and older age [16,22,23].
Regarding the distribution of comorbidities and symptoms on hospital admission, our
results are consistent with earlier studies in China [4,24,22,25], and with data from the Minis-
try of Health report on the status of COVID-19 in Spain as of 17 April 2020 [26]. In all series
studied to date, the comorbidities associated most frequently with COVID-19 were CVD, DM
and HT, and the most common clinical characteristics on admission were low-grade fever, dry
cough, general malaise, fatigue, and dyspnoea. In our series, the presence of ageusia showed
better prognosis of patients (HR 0.11; 95%CI 0.02–0.83) in the stepwise regression model
including age and the remaining symptomatologic variables. This symptom has reported to be
more frequent in younger patients and in women [27,28]. Therefore, ageusia might bias the
results as older age and male sex are associated with worse prognosis. Patients with cognitive
impairment also would present difficulties to detect and express this specific symptom. This
hypothesis should be tested in specific studies but, in any case, the association disappeared in
our final models fitted for each group of variables. Regarding smoking, although several stud-
ies have pointed a worse progression and adverse outcomes of COVID-19 [29,30], in our
Table 3. Hazard ratios for the associations of each laboratory parameter with hazard of death.
Group Variable1 HR2 95%CI HR3 95%CI HR4 95%CI
Laboratory values on admission Haemoglobin 1.00 0.88–1.13
Lymphocytes 1.00 0.99–1.00
Neutrophils 1.00 0.99–1.01
Glycaemia 1.01 1.00–1.01 1.01 1.00–1.01
D-dimer 1.00 0.99–1.00
Total bilirubin 1.00 0.89–1.11
Creatinine 0.99 0.94–1.05
Altered kidney function1 1.74 1.00–3.01
Ferritin 1.00 1.00–1.00






SOFA 1.24 1.14–1.35 1.17 1.08–1.30 1.19 1.05–1.34
CURB-65 2.44 1.85–3.21 2.53 1.81–3.55 1.73 1.23–2.43
1 Altered kidney function was considered as a dichotomous variable, with No as the reference category. All other variables are quantitative; hazard ratios are expressed as
increments in the hazard of death per unit increase in the variable.
2 Hazard ratios adjusted by age.
3 Hazard ratios obtained with stepwise regression models including age and the remaining laboratory variables.
4 Hazard ratios obtained with a stepwise regression model including all variables retained in the models fitted for each group of variables (see Table 2).
SOFA, Sequential Organ Failure Assessment score; CURB-65, Score on the Confusion Urea Respiratory and Blood pressure scale.
https://doi.org/10.1371/journal.pone.0235107.t003
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study we could not corroborate these results. Apart from the small number of current smokers
in our sample (only 22 patients and 3 deaths among them) which may lead to high variability
in the estimations for this subgroup, this fact might have two explanations. First, smoking hab-
its were not systematically collected in all clinical records. Therefore, the existence of a consid-
erable amount of missing data (42 patients) for this variable may have distorted the results.
Second, patients with high number of comorbidities (i.e., DM, pulmonary diseases or living in
retirement homes) might plausibly show a lower frequency of smoking habits given their con-
dition, whilst their intrinsic risk of mortality is high. Again, this hypothesis should be tested in
specific studies. Two findings from our crude analysis stand out: the low frequency of death in
our patients with no comorbidities (5.8%), and the high percentage of deaths among patients
with dependence for BADL (approaching 80%) and/or who lived in retirement homes. These
three variables are closely related with each other, and with older age, as shown by the Cox
regression models. Although we can venture no explanation for the reasons behind these rela-
tionships, these three variables alone or in combination appear to define a population group at
high risk of death, as also suggested in earlier studies [31–36]. We believe this high risk should
be taken into account in setting priorities for the indication for hospital admission. In particu-
lar, patients who live in retirement homes are likely to have most of the risk factors we identi-
fied, and in fact, it is estimated that nearly 12,200 older persons have died during the current
pandemic among residents of public, joint public–private, and private retirement facilities in
Spain [37]. This makes it imperative to develop specific, co-ordinated actions across all such
centres during the epidemic, in order to ensure that the necessary material and human
resources are available to care for these especially vulnerable patients. To date, few studies have
analysed the causes of higher morbidity and mortality in this population group [38,39], and no
such studies have been done in Spain. Our findings suggest the need for a specific approach to
care for this group both in hospital emergency services and in residential retirement facilities.
The models we obtained with our adjusted analysis showed that in our series of patients
hospitalized for COVID-19, characteristics present before SARS-CoV-2 infection that were
independently associated mortality were age (exponential increase in patients 50 years old and
older) and DM. A study from China based on a retrospective cohort of 191 patients identified
CVD and DM as chronic diseases associated with greater mortality. However, in contrast to
our finding for DM, Zhou and colleagues found that this association disappeared in their
adjusted analysis [16]. In this study, associations were detected only for patient age (odds ratio
1.10 per 1-year increase in age, 95% confidence interval [95%CI] 1.03–1.17).
At least one other review of comorbidities associated with COVID-19 found that CVD and
DM were among the factors most strongly associated with an increased risk of mortality,
although this was based only on crude data [40].
With regard to baseline variables relating to the characteristics of SARS-CoV-2 infection on
admission, those that yielded independent associations with mortality were greater need for
externally supplied oxygen to maintain adequate saturation (low SatO2/FiO2 ratio as a result of
ARDS) and high SOFA and CURB-65 scores. These findings are consistent with factors identi-
fied in earlier reports from countries other than Spain [7,16,41–43]. Zhou and colleagues [16]
detected two risk parameters measured on admission: SOFA score (odds ratio 5.65, 95%CI
2.61–12.23) and D-dimer concentration greater than 1 μg/ml (odds ratio 18.42, 95%CI 2.64–
128.55). Although D-dimer has been consistently associated with higher mortality [44,45], we
could not corroborate these results in our study.
As noted in the Methods section, the main limitation of this study is the selection bias
resulting from out inclusion criteria: patients who were either discharged or died, excluding
those who were still hospitalized at the end of the recruitment period. Nonetheless, we feel the
use of Cox regression models minimized the impact of this bias on the magnitude of our
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estimated associations, given that the estimates were a function of time to death. Because our
patients comprise the first sample of people admitted with the characteristics reported here,
the duration of follow-up was brief and this may have led to the selection of “extreme” cases,
i.e. those who were the first to be discharged or the first to die in our hospital. This factor
makes our findings especially useful for studies of the first patients to be hospitalized in other
settings. These considerations, along with the chronology of the COVID-19 pandemic in
Spain, make it likely that the patients selected for this study differed from those who were still
hospitalized at the end of the recruitment period. In other words, compared to subsequently
admitted patients, those analysed here may have had more and/or more severe clinical signs
and symptoms as grounds for admission. Another potential source of error is the lack of
adjustment for variables we did not measure, either because they were not recorded in the
medical records or were not considered relevant in light of our current (incomplete, constantly
changing) knowledge of COVID-19. There is another potential bias concerning the selection
of patients which are mainly elderly patients coming from a localized region in Spain. There-
fore, the results could not be widely generalized. A final consideration is that we designed a
monocentric study with a limited number of patients, while a great number of different factors
were analysed as independent variables. This limited sample size necessitated a sequential pro-
cess to develop our models, with a stepwise approach and low number of predictive variables.
Conclusions
In addition to the close association between mortality and comorbidities, dependence for
BADL and living in a retirement facility in our crude analysis, the main baseline factors that
were independently associated in our adjusted analysis with mortality in patients hospitalized
for COVID-19 were older age, DM, low SatO2/FiO2 ratio, and high SOFA and CURB-65
scores. These characteristics define a profile of patients in Spain with an elevated mortality rate
for whom a specific approach to clinical management is urgently needed.
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Rodrı́guez, Pedro Antonio Guirado-Ruiz, Antonio Jesús Láinez-Ramos-Bossini.
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